Improving prognosis in hepatorenal syndrome

Gut

Volumn 47, Issue 2, 2000, Pages 166-167

  Mccormick, P A ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; MIDODRINE; OCTREOTIDE; ORNIPRESSIN; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ASCITES; BLOOD VOLUME; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; LIVER FAILURE; NOTE; PARACENTESIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS;

HEPATORENAL SYNDROME; HUMANS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROGNOSIS; VASOCONSTRICTOR AGENTS;

EID: 0033915685     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.2.166     Document Type: Note

References (11)

1. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-76.
2. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-36.
3. Yersin B, Burnier M, Magnenat P. Improvement of renal failure with repeated head-out water immersions in patients with hepatorenal syndrome associated with alcoholic hepatitis. Am J Nephrol 1995;15:260-5.
4. Jeyarajah DR, Gonwa TA, McBride M, et al. Hepatorenal syndrome: Combined liver kidney transplants versus isolated liver transplant. Transplantation 1997;64:1760-5.
5. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47:288-95.
6. Lebrec D, Giuily N, Hadengue A, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 1996;25:135-44.
7. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatalogy 1999;29:1690-7.
8. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999;30:870-5.
9. Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-70.
10. Lafayette RA, Pare G, Schmid CH, King AJ, Rohrer RJ, Nasaway SA. Pre- transplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol 1997;48:159-64.
11. Sort P, Navasa M, Aroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9.